- Home
- SAVA vs KBSX Comparison
SAVA vs KBSX Comparison
Compare SAVA & KBSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- KBSX
- Stock Information
- Founded
- SAVA 1998
- KBSX N/A
- Country
- SAVA United States
- KBSX Taiwan
- Employees
- SAVA N/A
- KBSX N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- KBSX Recreational Games/Products/Toys
- Sector
- SAVA Health Care
- KBSX Consumer Discretionary
- Exchange
- SAVA Nasdaq
- KBSX Nasdaq
- Market Cap
- SAVA 113.8M
- KBSX 104.0M
- IPO Year
- SAVA N/A
- KBSX N/A
- Fundamental
- Price
- SAVA $2.55
- KBSX $6.78
- Analyst Decision
- SAVA Buy
- KBSX
- Analyst Count
- SAVA 3
- KBSX 0
- Target Price
- SAVA $111.50
- KBSX N/A
- AVG Volume (30 Days)
- SAVA 1.3M
- KBSX 9.4K
- Earning Date
- SAVA 03-07-2025
- KBSX 04-25-2025
- Dividend Yield
- SAVA N/A
- KBSX N/A
- EPS Growth
- SAVA N/A
- KBSX N/A
- EPS
- SAVA N/A
- KBSX N/A
- Revenue
- SAVA N/A
- KBSX $33,935,076.00
- Revenue This Year
- SAVA N/A
- KBSX N/A
- Revenue Next Year
- SAVA N/A
- KBSX N/A
- P/E Ratio
- SAVA N/A
- KBSX N/A
- Revenue Growth
- SAVA N/A
- KBSX N/A
- 52 Week Low
- SAVA $2.23
- KBSX $5.24
- 52 Week High
- SAVA $42.20
- KBSX $15.48
- Technical
- Relative Strength Index (RSI)
- SAVA 41.47
- KBSX N/A
- Support Level
- SAVA $2.25
- KBSX N/A
- Resistance Level
- SAVA $2.36
- KBSX N/A
- Average True Range (ATR)
- SAVA 0.14
- KBSX 0.00
- MACD
- SAVA 0.17
- KBSX 0.00
- Stochastic Oscillator
- SAVA 50.85
- KBSX 0.00
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.